Immunitas Therapeutics and Lonza Announce Manufacturing Agreement to Rapidly Advance Lead Program to the Clinic April 16, 2021
Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology February 18, 2021
Abveris Announces Antibody Discovery Agreement with Immunitas Using the Berkeley Lights Beacon® October 8, 2020
Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics December 18, 2019
